All articles tagged with #tourmaline bio
Novartis plans to acquire Tourmaline Bio for approximately USD 1.4 billion, gaining access to the Phase 3 ready asset pacibekitug, an anti-IL-6 monoclonal antibody targeting systemic inflammation in atherosclerotic cardiovascular disease, which shows promising results in reducing inflammation markers and addresses an unmet need in cardiovascular risk reduction.
Talaris Therapeutics and Tourmaline Bio have announced a merger agreement to create a Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). The combined company is expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors. Talaris stockholders are expected to receive approximately $3.43 per Talaris share, including a cash dividend up to approximately $64.8 million and approximately 21.3% of the combined company.